Jul 18, 2018
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
Jun 27, 2018
SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting
Jun 11, 2018
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
May 24, 2018
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
May 23, 2018
SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention
May 08, 2018
SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
May 01, 2018
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Apr 23, 2018
SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
Apr 10, 2018
SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
Mar 21, 2018
SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference
Mar 20, 2018
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
Mar 13, 2018
SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
Mar 07, 2018
SCYNEXIS to Present at the 30th Annual ROTH Conference
Mar 05, 2018
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
Feb 01, 2018
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
Jan 11, 2018
SCYNEXIS to Participate in the Cantor Antibiotics Summit
Jan 04, 2018
SCYNEXIS Provides Corporate and SCY-078 Pipeline Update
Nov 22, 2017
SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference
Nov 07, 2017
SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
Jun 19, 2017
Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel